Literature DB >> 22976497

Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy.

Seiji Mabuchi1, Mika Okazawa, Yasuto Kinose, Koji Matsuo, Masateru Fujiwara, Osamu Suzuki, Eiichi Morii, Shoji Kamiura, Kazuhiko Ogawa, Tadashi Kimura.   

Abstract

OBJECTIVES: To evaluate the significance of adenosquamous carcinoma (ASC) compared with adenocarcinoma (AC) in the survival of surgically treated early-stage cervical cancer.
METHODS: We retrospectively reviewed the medical records of 163 patients with International Federation of Gynecology and Obstetrics stage IA2 to stage IIB cervical cancer who had been treated with radical hysterectomy with or without adjuvant radiotherapy between January 1998 and December 2008. The patients were classified according to the following: (1) histological subtype (ASC group or AC group) and (2) pathological risk factors (low-risk or intermediate/high-risk group). Survival was evaluated using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis of progression-free survival (PFS) was performed using the Cox proportional hazards regression model to investigate the prognostic significance of histological subtype.
RESULTS: Clinicopathological characteristics were similar between the ASC and AC histology groups. Patients with the ASC histology displayed a PFS rate similar to that of the patients with the AC histology in both the low-risk and intermediate/high-risk groups. Neither the recurrence rate nor the pattern of recurrence differed between the ASC group and the AC group. Univariate analysis revealed that patients with pelvic lymph node metastasis and parametrial invasion achieved significantly shorter PFS than those without these risk factors.
CONCLUSIONS: Characteristics of the patients and the tumors as well as survival outcomes of ASC were comparable to adenocarcinoma of early-stage uterine cervix treated with radical hysterectomy. Our results in part support that the management of ASC could be the same as the one of AC of the uterine cervix.

Entities:  

Mesh:

Year:  2012        PMID: 22976497     DOI: 10.1097/IGC.0b013e31826b5d9b

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis.

Authors:  Juan Zhou; San-Gang Wu; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Qiong-Hua Chen; Zhen-Yu He
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-19       Impact factor: 4.553

2.  Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.

Authors:  Eriko Yokoi; Seiji Mabuchi; Ryoko Takahashi; Yuri Matsumoto; Hiromasa Kuroda; Katsumi Kozasa; Tadashi Kimura
Journal:  J Gynecol Oncol       Date:  2016-12-08       Impact factor: 4.401

3.  The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma.

Authors:  Yawen Liu; Haiyan Tu; Lingling Zhang; Meiling Zhong; Yanan Wang; Ling Li; Xiaojun Xiang
Journal:  BMC Womens Health       Date:  2022-04-12       Impact factor: 2.809

4.  Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management.

Authors:  Angel Yordanov; Stoyan Kostov; Stanislav Slavchev; Strahil Strashilov; Assia Konsoulova; Jean Calleja-Agius; Riccardo Di Fiore; Sherif Suleiman; Paul Kubelac; Catalin Vlad; Patriciu Achimas-Cadariu; Mariela Vasileva-Slaveva
Journal:  Cancer Manag Res       Date:  2021-06-23       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.